Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus PANIXINE DISPERDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus PANIXINE DISPERDOSE.
CEFUROXIME SODIUM vs PANIXINE DISPERDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic